EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinical Outcomes in Double‐Exposed Chronic Lymphocytic Leukemia Patients in Italy

Francesco Autore iD, Andrea Visentin, Candida Vitale, Diana Giannarelli, Alberto Fresa, Francesca Morelli, Veronica Mattiello, Gioacchino Catania, Riccardo Moia iD, Giulia Quaresmini, Annamaria Giordano, Ilaria Scortechini und 9 weitere

Hematological Oncology · 2026-03 · 44 (2)

DOI: 10.1002/hon.70184 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hematological Oncology, online erschienen am 04.03.2026. Verfasst von Francesco Autore und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory and Haematological Sciences, Haematology Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B‐cell receptor inhibitors (BCRi) and B‐cell lymphoma‐2 inhibitor (BCL2i) improved outcomes of patients with chronic lymphocytic leukemia (CLL), but relapsing after two inhibitors still represent an unmet clinical need. This multicenter real‐world study analyzes outcomes of a cohort treated in Italy between May 2017 and September 2023 following prior exposure to both BCRi and BCL2i. The median follow‐up after venetoclax initiation was 47 months (IQR 28–56). Of 153 double‐exposed patients, 104 (68%) discontinued venetoclax and 53 of them (51%) received a subsequent treatment. Venetoclax was discontinued due to progressive disease (PD) in 51/104 cases (49.0%), with nine deaths occurring rapidly after PD without the administration of any further treatment. Fifty‐three patients received treatment after venetoclax: 29/53 (54.7%) received inhibitors (13 cBTKi, 11 idelalisib, 2 BCL2i, 3 non‐covalent BTKi), 19/53 (35.8%) received chemoimmunotherapy (CT: 16 intensive, 3 palliative), 5/53 (9.4%) received hematopoietic stem cell transplantation (HSCT). Overall response rate was 50%; median event free survival (EFS) in the groups of inhibitors, CT and HSCT was 11, 2, and 10 months, respectively ( p < 0.0001); median overall survival (OS) was 12, 5, and 10 months, respectively ( p = 0.020). Disease progression during venetoclax treatment was associated with shorter subsequent EFS compared to discontinuation for other reasons, even if the finding did not reach statistical significance (median EFS 4 vs. 10 months; p = 0.11). No decrease in EFS was associated with del17p and/or TP53 mutations, the use of venetoclax monotherapy or a previous treatment with one versus multiple BCRi. Despite its limitations, this real‐world study provides additional insights into double‐exposed patients, who still pose a clinical challenge, demonstrating the superior efficacy of inhibitors over alternative treatment options. Enrollment in clinical trial and treatments with novel molecules, if available, may help address this unmet clinical need.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellBridged Bicyclo Compounds, HeterocyclicAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleSulfonamidesAgedItalyMiddle Aged

Stichwörter der Autor:innen

BTKiCLLvenetoclax

Substanzen

Bridged Bicyclo Compounds, HeterocyclicvenetoclaxSulfonamides

Autor:innen und Institutionen

  • Department of Laboratory and Haematological Sciences, Haematology Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
  • Università degli Studi di Padova, Padova, Italy.
  • Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
  • University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy.
  • Facility of Epidemiology and Biostatistics, GSTeP, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
  • Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", Napoli, Italy.

ORCID-Profile: Francesco Autore, Riccardo Moia, Lucia Farina, Paolo Sportoletti, Alessandro Sanna

Zitieren

APA

Autore, F., Visentin, A., Vitale, C., Giannarelli, D., Fresa, A., Morelli, F., Mattiello, V., Catania, G., Moia, R., Quaresmini, G., Giordano, A., Scortechini, I., Farina, L., Sportoletti, P., Gentile, M., Angeletti, I., Innocenti, I., Sanna, A., Coscia, M., …, & Laurenti, L. (2026). Clinical Outcomes in Double‐Exposed Chronic Lymphocytic Leukemia Patients in Italy. Hematological Oncology, 44(2). https://doi.org/10.1002/hon.70184

Vancouver

Autore F, Visentin A, Vitale C, Giannarelli D, Fresa A, Morelli F, et al. Clinical Outcomes in Double‐Exposed Chronic Lymphocytic Leukemia Patients in Italy. Hematological Oncology. 2026;44(2). doi:10.1002/hon.70184

BibTeX
@article{Autore2026,
  author = {Autore, Francesco and Visentin, Andrea and Vitale, Candida and Giannarelli, Diana and Fresa, Alberto and Morelli, Francesca and Mattiello, Veronica and Catania, Gioacchino and Moia, Riccardo and Quaresmini, Giulia and Giordano, Annamaria and Scortechini, Ilaria and Farina, Lucia and Sportoletti, Paolo and Gentile, Massimo and Angeletti, Ilaria and Innocenti, Idanna and Sanna, Alessandro and Coscia, Marta and Trentin, Livio and Laurenti, Luca},
  title = {Clinical Outcomes in Double‐Exposed Chronic Lymphocytic Leukemia Patients in Italy},
  journal = {Hematological Oncology},
  year = {2026},
  volume = {44},
  number = {2},
  doi = {10.1002/hon.70184}
}
Kostenlos starten →